This text additionally provides an authoritative state of the art review of the preclinical and clinical aspects of haematological malignancies and how they might impact precision oncology becoming the standard of care. It is concise, easily readable, and yet provides an authoritative review of the ‘state of the art’.

Many experts now consider genetic evaluation to be pivotal for the optimal diagnosis, classification, risk stratification, and therapeutic decision-making for persons diagnosed with blood cancer. This new text specifically focuses on the genetic alterations essential for establishing diagnosis and assesses how they might impact the precision oncology standard of care. Providing an authoritative review of the state of the art, this is essential reading for physicians, hematologists, and oncologists for optimal management of individual patients.